FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody that specifically binds to human C5a, as well as to a method for reducing the activity of the complement system of an individual using it. Also disclosed is a cell for producing an antibody, which contains a nucleic acid encoding the above antibody.
EFFECT: invention is effective for treating a complement-mediated disease or disorder in an individual.
19 cl, 7 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| HUMANIZED ANTIBODIES TO THE THOMSEN-FRIEDENREICH ANTIGEN | 2015 |
|
RU2699717C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
